Therapeutic Areas

Home > Clinical Research Trials > Therapeutic Areas > Anemia in patients with Chronic Kidney Disease

This trial will demonstrate the safety and effectiveness of a new injected drug to correct anemia for patients with CRF that are not currently on ESA (Erythropoiesis Stimulating Agent) Treatment. It is also an attempt to demonstrate how the new study drug compares with other currently marketed drugs for the same diagnosis.

Treatment will last a minimum of 52 weeks. There will be 19 visits within the first 36 weeks over which time appropriate adjustments are made to create a custom, optimal dosage for each individual patient. After that time (week 38) visits will be every 2 weeks until the end of the trial, monitored and further adjusted as necessary.

• Latest News

  • CenterWatch Monthly January 2009
  • PPD and Merck in Strategic Outsourcing Deal

• • Medical Research Offers No-Cost Healthcare Option for Patient Volunteers with Flu

• Archives

  Select Month January 2009 September 2008 August 2008 June 2008 April 2008 November 2007 October 2007 September 2007 August 2007

Best Practices and Research Ruminations

• cSSSIs and MRSA

Submit Comments, Links or News